Napsin A is a useful marker for metastatic adenocarcinomas of pulmonary origin

Histopathology

Volumn 65, Issue 2, 2014, Pages 195-206

  Kim, Moon Young ^a,b   Go, Heounjeong ^a,b,c   Koh, Jaemoon ^a,b   Lee, Kyoungbun ^a,b   Min, Hye Sook ^a,b   Kim, Min A ^a,b   Jeon, Yoon Kyung ^a,b   Lee, Hye Seung ^b,d   Moon, Kyung Chul ^a,b   Park, So Yeon ^b,d   Kim, Woo Ho ^a,b   Chung, Doo Hyun ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

Author keywords

Immunohistochemistry; Metastasis; Napsin A; Origin of adenocarcinoma; Pulmonary adenocarcinoma

Indexed keywords

ASPARTIC PROTEINASE; CYTOKERATIN 20; CYTOKERATIN 7; NAPSIN A; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; NAPSA PROTEIN, HUMAN; TTF1 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADRENAL METASTASIS; ANTIGENICITY; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CLEAR CELL ADENOCARCINOMA; COLON ADENOCARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LUNG ADENOCARCINOMA; LUNG TUMOR; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; THYROID CARCINOMA; TISSUE MICROARRAY; BIOSYNTHESIS; PATHOLOGY;

ADENOCARCINOMA; ASPARTIC ACID ENDOPEPTIDASES; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NEOPLASM METASTASIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904402643     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12383     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA-Cancer J. Clin. 2013; 63; 11-30.
2. Devesa SS, Bray F, Vizcaino AP et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int. J. Cancer 2005; 117; 294-299.
3. Lee JG, Lee CY, Bae MK et al. Changes in the demographics and prognoses of patients with resected non-small cell lung cancer: a 20-year experience at a single institution in Korea. J. Korean Med. Sci. 2012; 27; 1486-1490.
4. Siegel R, DeSantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA-Cancer J. Clin. 2012; 62; 220-241.
5. Larsen JE, Cascone T, Gerber DE et al. Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J. 2011; 17; 512-527.
6. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study Of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 2011; 6; 244-285.
7. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in tumor diagnosis: a review and update. Appl. Immunohistochem. Mol. Morphol. 2012; 20; 429-444.
8. Matoso A, Singh K, Jacob R et al. Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl. Immunohistochem. Mol. Morphol. 2010; 18; 142-149.
9. Wieczorek TJ, Pinkus JL, Glickman JN et al. Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma. Am. J. Clin. Pathol. 2002; 118; 911-921.
10. Robens J, Goldstein L, Gown AM et al. Thyroid transcription factor-1 expression in breast carcinomas. Am. J. Surg. Pathol. 2010; 34; 1881-1885.
11. Ye J, Hameed O, Findeis-Hosey JJ et al. Diagnostic utility of PAX8, TTF-1 and napsin A for discriminating metastatic carcinoma from primary adenocarcinoma of the lung. Biotech. Histochem. 2012; 87; 30-34.
12. Verset L, Arvanitakis M, Loi P et al. TTF-1 positive small cell cancers: don't think they're always primary pulmonary!. World J. Gastrointest. Oncol. 2011; 3; 144-147.
13. Chuman Y, Bergman A, Ueno T et al. Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett. 1999; 462; 129-134.
14. Schauer-Vukasinovic V, Bur D, Kling D et al. Human napsin A: expression, immunochemical detection, and tissue localization. FEBS Lett. 1999; 462; 135-139.
15. Hirano T, Auer G, Maeda M et al. Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A. Jpn. J. Cancer Res. 2000; 91; 1015-1021.
16. Suzuki A, Shijubo N, Yamada G et al. Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol. Res. Pract. 2005; 201; 579-586.
17. Hirano T, Gong Y, Yoshida K et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer 2003; 41; 155-162.
18. Turner BM, Cagle PT, Sainz IM et al. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch. Pathol. Lab. Med. 2012; 136; 163-171.
19. Ordonez NG. Napsin A expression in lung and kidney neoplasia: a review and update. Adv. Anat. Pathol. 2012; 19; 66-73.
20. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum. Pathol. 2010; 41; 20-25.
21. Ordonez NG. A word of caution regarding napsin A expression in squamous cell carcinomas of the lung. Am. J. Surg. Pathol. 2012; 36; 396-401.
22. Kadivar M, Boozari B. Applications and limitations of immunohistochemical expression of 'Napsin-A' in distinguishing lung adenocarcinoma from adenocarcinomas of other organs. Appl. Immunohistochem. Mol. Morphol. 2013; 21; 191-195.
23. Ye J, Findeis-Hosey JJ, Yang Q et al. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl. Immunohistochem. Mol. Morphol. 2011; 19; 313-317.
24. Fatima N, Cohen C, Lawson D et al. TTF-1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks. Cancer Cytopathol. 2011; 119; 127-133.
25. Dejmek A, Naucler P, Smedjeback A et al. Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. Diagn. Cytopathol. 2007; 35; 493-497.
26. Kim JH, Kim YS, Choi YD et al. Utility of napsin A and thyroid transcription factor 1 in differentiating metastatic pulmonary from non-pulmonary adenocarcinoma in pleural effusion. Acta Cytol. 2011; 55; 266-270.
27. Mukhopadhyay S, Katzenstein AL. Comparison of monoclonal napsin A, polyclonal napsin A, and TTF-1 for determining lung origin in metastatic adenocarcinomas. Am. J. Clin. Pathol. 2012; 138; 703-711.
28. Inamura K, Satoh Y, Okumura S et al. Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am. J. Surg. Pathol. 2005; 29; 660-665.
29. Ozcan A, de la Roza G, Ro JY et al. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison. Arch. Pathol. Lab. Med. 2012; 136; 1541-1551.
30. Fadare O, Desouki MM, Gwin K et al. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Am. J. Surg. Pathol. 2013; 38; 189-196.
31. Skirnisdottir I, Bjersand K, Akerud H et al. Napsin A as a marker of clear cell ovarian carcinoma. BMC Cancer 2013; 13; 524.
32. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am. J. Surg. Pathol. 2008; 32; 1566-1571.